- You are viewing a Navigating Care library resource.
- Back to Library
Chronic Myelogenous Leukemia
Chronic myelogenous leukemia is a disease in which too many white blood cells are made in the bone marrow. See the PDQ summary on Chronic Myelogenous Leukemia Treatment for information on diagnosis, staging, and treatment.
This information is not intended to replace the advice of a doctor.
Navigating Care disclaims any liability for the decisions you make based on this information.
This information was sourced and adapted from Adapted from the National Cancer Institute's
Physician Data Query (PDQ®) Cancer Information Summaries on
www.cancer.gov.
This information updated
November 1, 2024.
Learn more:
- General Information About Chronic Myeloproliferative Neoplasms
- Chronic Myelogenous Leukemia
- Polycythemia Vera
- Primary Myelofibrosis
- Essential Thrombocythemia
- Chronic Neutrophilic Leukemia
- Chronic Eosinophilic Leukemia
- Stages of Chronic Myeloproliferative Neoplasms
- Treatment Option Overview
- Treatment of Chronic Myelogenous Leukemia
- Treatment of Polycythemia Vera
- Treatment of Primary Myelofibrosis
- Treatment of Essential Thrombocythemia
- Treatment of Chronic Neutrophilic Leukemia
- Treatment of Chronic Eosinophilic Leukemia
- To Learn More About Chronic Myeloproliferative Neoplasms
Related Articles
- General Information About Chronic Myeloproliferative Neoplasms
- Chronic Myelogenous Leukemia
- Polycythemia Vera
- Primary Myelofibrosis
- Essential Thrombocythemia
- Chronic Neutrophilic Leukemia
- Chronic Eosinophilic Leukemia
- Stages of Chronic Myeloproliferative Neoplasms
- Treatment Option Overview
- Treatment of Chronic Myelogenous Leukemia
- Treatment of Polycythemia Vera
- Treatment of Primary Myelofibrosis
- Treatment of Essential Thrombocythemia
- Treatment of Chronic Neutrophilic Leukemia
- Treatment of Chronic Eosinophilic Leukemia
- To Learn More About Chronic Myeloproliferative Neoplasms
See Expert Resources
The Navigating Care Library includes articles about cancer, chemotherapy regimens and drugs from the
the National Cancer Institute and other experts.
